Fig. 1 · Structure

Documents & Downloads

MPTP hydrochloride

Cat. No. A15173 CAS 23007-85-4

DA neurotoxin

MPTP hydrochloride induced reduction in the DOPAC HVA/dopamine (DA) ratio and increase in striatal ascorbate (AS) oxidation in rats.

In Stock

Publications for MPTP hydrochloride

2 publications citing this product

  1. Sai Teja Meka, .et al. , Eur J Pharmacol, 2023, Nov 15:959:176067 PMID: 37751833
  2. Philemon Dauda Shallie, .et al. , Annual Research & Review in Biology, 2017, 13(5): 1-11

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

MPTP is a precursor of MPP+. In a purified MAO-B preparation, the intermediate MPDP+ appeared before later MPP+ accumulation. This supports metabolic activation; it does not establish exclusive MAO-B dependence in vivo. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

MPTP hydrochloride Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of MPTP hydrochloride from 2 published references. In vitro models include purified MAO-B preparation; immortalized mouse astrocytes, IMA 2.1. In vivo models include male C57BL/6 mice, 8–10 weeks old.

MPTP hydrochloride In Vitro Studies

In immortalized mouse astrocytes exposed to MPTP, MPP+ accumulated predominantly outside the cells. This compartmental observation distinguishes MPTP metabolism from experiments that directly expose cells to MPP+. [1]

MPTP metabolite sequence in a purified MAO-B preparation

Biochemical assay · Purified MAO-B preparation [1]

MPTP depletion was accompanied by early MPDP+ and later MPP+ accumulation. This time course supports metabolic activation but does not establish exclusive MAO-B dependence in vivo.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MPTP, MPDP+ and MPP+ time coursesTemporal metabolite profile MPDP+ appeared before the later accumulation of MPP+; mean ± SD, n = 3. No exact curve values extracted.[1]

Literature-Reported Treatment Conditions

Treatment concentration
MPTP 30 μM; purified MAO-B 1 U/ml
Exposure duration
0–48 h as plotted in Fig. 2A
Method
Cell-free incubation followed by HPLC metabolite analysis
Reported limits
An enzyme-free control is not displayed in the selected panel; no claim of enzyme exclusivity is made. Incubation vehicle is not specified in the selected caption.
Methods and source locations

Compound reported in the paper: MPTP hydrochloride; Compound label in the paper: MPTP-HCl

Literature evidence for MPTP hydrochloride as reported; no supplier equivalence, lot verification, salt conversion or clinical efficacy is implied.

Fig. 2A and caption; Results: MPDP+ is a membrane-crossing intermediate; Materials: MPTP-HCl identity and HPLC analysis

MPTP, MPDP+ and MPP+ time courses: HPLC with individual compound standard curves — Fig. 2A, caption; HPLC analysis

Extracellular predominance of MPP+ after astrocytic MPTP exposure

Cell-based study · Immortalized mouse astrocytes, IMA 2.1 [1]

Following MPTP exposure, MPP+ accumulated predominantly in the extracellular compartment rather than within IMA 2.1 cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intracellular versus extracellular MPP+Compartmental distribution Extracellular MPP+ increased over the observed days while intracellular MPP+ remained low; mean ± SD, n = 3. No exact curve concentrations extracted.[1]

Literature-Reported Treatment Conditions

Treatment concentration
MPTP 20 μM
Exposure duration
0–3 days as plotted in Fig. 1D
Method
IMA 2.1 exposure with paired intracellular and supernatant analysis
Reported limits
The selected panel compares compartments and time points; it is not a vehicle-controlled cell-death assay. Vehicle is not specified in that caption.
Methods and source locations

Compound reported in the paper: MPTP hydrochloride; Compound label in the paper: MPTP-HCl

Literature evidence for MPTP hydrochloride as reported; no supplier equivalence, lot verification, salt conversion or clinical efficacy is implied.

Fig. 1D and caption; Results: Extracellular MPP+ generation; Materials: IMA 2.1 astrocytes and HPLC analysis

Intracellular versus extracellular MPP+: HPLC of cell-associated and supernatant fractions — Fig. 1D and caption; first Results subsection

MPTP hydrochloride In Vivo Studies

In male C57BL/6 mice, the MPTP-hydrochloride/vehicle group had lower nigral TH-positive neuron counts and locomotor activity than saline controls. The MDL-28170/MPTP group had higher counts and activity than MPTP/vehicle, but striatal dopamine was not restored and terminal deficits persisted. This comparison does not demonstrate complete nigrostriatal recovery or drug-target specificity. [2]

Nigral and functional endpoints in an MPTP mouse model

Animal study · Male C57BL/6 mice, 8–10 weeks old [2]

MPTP/vehicle mice had lower nigral TH-positive neuron counts and locomotor activity than saline controls. The MDL-28170/MPTP group had higher counts and activity than MPTP/vehicle, while striatal dopamine remained reduced.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Estimated nigral TH-positive neuron population, day 14Neuron count Saline: 12259 ± 837.8; VEH-MPTP: 6854 ± 859.5; MDL-MPTP: 10069 ± 629.6. Group mean ± SEM; Fig. 3 caption reports eight mice per group.[2]
Spontaneous horizontal locomotor activityDistance traveled MPTP with vehicle reduced activity; MDL-MPTP improved activity relative to VEH-MPTP and was not significantly different from saline. Mean ± SEM; n = 6–9 per group per treatment.[2]
Striatal dopaminergic terminals and dopamineQualitative comparison Both MPTP groups retained striatal TH-fiber deficits versus saline; MDL only partially mitigated fiber loss. Striatal dopamine was not restored by MDL. Fig. 7 reports mean ± SEM, n = 6–8 per group.[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Saline referenceUnlesioned referenceTable 3, 14 d TH: 12259 ± 837.8 neurons (mean ± SEM).[2]
MPTP with inhibitor vehicle
MPTP 25 mg/kg, measured as free base
Saline referenceTable 3, 14 d TH: 6854 ± 859.5 neurons (mean ± SEM); locomotor activity and striatal dopamine were reduced.[2]
MPTP with MDL-28170
MPTP 25 mg/kg, measured as free base; MDL-28170 pump solution 160 μM
MPTP plus vehicle and saline referenceTable 3, 14 d TH: 10069 ± 629.6 neurons (mean ± SEM). Locomotor activity improved, but striatal dopamine was not restored.[2]
Saline reference
Model: Male C57BL/6 mice, 8–10 weeks old
Route: Intraperitoneal
Frequency: Once daily
Treatment course: 5 consecutive days; endpoints around 2 weeks from initiation
Vehicle: 0.9% saline
MPTP with inhibitor vehicle
Model: Male C57BL/6 mice, 8–10 weeks old
Route: MPTP intraperitoneal; inhibitor vehicle intracerebroventricular
Frequency: MPTP once daily
Treatment course: MPTP for 5 consecutive days; vehicle pump implanted 24 h before first exposure
Vehicle: MPTP saline; inhibitor vehicle Krebs’–Ringer’s solution
Reported limits: The control pump vehicle is identified as Krebs’–Ringer’s; matching of cyclodextrin/DMSO to the inhibitor solution is not explicit in the selected methods.
MPTP with MDL-28170
Model: Male C57BL/6 mice, 8–10 weeks old
Route: MPTP intraperitoneal; MDL-28170 intracerebroventricular
Frequency: MPTP once daily; MDL delivered by implanted pump
Treatment course: MPTP for 5 consecutive days; MDL pump implanted 24 h before first exposure
Vehicle: MPTP saline; MDL in Krebs’–Ringer’s solution containing 10% cyclodextrins, diluted from a DMSO stock
Methods and source locations

Compound reported in the paper: MPTP hydrochloride; Compound label in the paper: MPTP-HCl

Literature evidence for MPTP hydrochloride as reported; no supplier equivalence, lot verification, salt conversion or clinical efficacy is implied.

Materials: MPTP, Calpain inhibition, Assessment of neuronal loss, behavioral and HPLC methods; Fig. 1B; Fig. 3/Table 3; Figs. 5A, 6 and 7

Estimated nigral TH-positive neuron population, day 14: TH immunohistochemistry with Abercrombie correction — Table 3, 14 d TH row and footnote; Fig. 3 caption

Spontaneous horizontal locomotor activity: Video-tracked distance in a novel environment over 60 min — Fig. 5A and caption; Results: MPTP-induced hypolocomotion

Striatal dopaminergic terminals and dopamine: TH/DAT immunohistochemistry and HPLC dopamine analysis — Figs. 6 and 7, captions; Results: Calpain inhibition and striatal denervation

Saline reference · Materials: MPTP and Calpain inhibition; Fig. 1B; Fig. 3 and Table 3; Figs. 5A, 6 and 7

MPTP with inhibitor vehicle · Materials: MPTP and Calpain inhibition; Fig. 1B; Fig. 3 and Table 3; Figs. 5A, 6 and 7

MPTP with MDL-28170 · Materials: MPTP and Calpain inhibition; Fig. 1B; Fig. 3 and Table 3; Figs. 5A, 6 and 7

Specifications

Manufacturer Adooq Bioscience
CAS Number 23007-85-4
Applications DA neurotoxin
Formula C12H15N.HCl
Molecular Weight 209.71
SMILES
CN1CCC(=CC1)C2=CC=CC=C2.Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 17 mg/mL (81.06 mM)
Water 36 mg/mL (171.65 mM)
Ethanol 36 mg/mL (171.65 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

MPTP hydrochloride Research References

  1. [1] Schildknecht S, Pape R, Meiser J, et al. Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+. Antioxidants & redox signaling (2015). PMID: 26413876 DOI: 10.1089/ars.2015.6297 Source material
  2. [2] Crocker SJ, Smith PD, Jackson-Lewis V, et al. Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience (2003). PMID: 12764095 DOI: 10.1523/jneurosci.23-10-04081.2003 Source material

Publications

2 publications citing this product

  1. Sai Teja Meka, .et al. , Eur J Pharmacol, 2023, Nov 15:959:176067 PMID: 37751833
  2. Philemon Dauda Shallie, .et al. , Annual Research & Review in Biology, 2017, 13(5): 1-11

Added to your cart

View Cart Checkout
Loading...